AU2024307335A1 - Pharmaceutical composition containing uracil derivative - Google Patents

Pharmaceutical composition containing uracil derivative

Info

Publication number
AU2024307335A1
AU2024307335A1 AU2024307335A AU2024307335A AU2024307335A1 AU 2024307335 A1 AU2024307335 A1 AU 2024307335A1 AU 2024307335 A AU2024307335 A AU 2024307335A AU 2024307335 A AU2024307335 A AU 2024307335A AU 2024307335 A1 AU2024307335 A1 AU 2024307335A1
Authority
AU
Australia
Prior art keywords
compound
cov
sars
infection
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2024307335A
Other languages
English (en)
Inventor
Jun Sato
Hiromitsu Shibayama
Shota Uehara
Yuto Unoh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Publication of AU2024307335A1 publication Critical patent/AU2024307335A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2024307335A 2023-10-05 2024-10-04 Pharmaceutical composition containing uracil derivative Pending AU2024307335A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2023173420 2023-10-05
JP2023-173420 2023-10-05
JP2024096866 2024-06-14
JP2024-096866 2024-06-14
PCT/JP2024/035560 WO2025005306A1 (ja) 2023-10-05 2024-10-04 ウラシル誘導体を含有する医薬組成物

Publications (1)

Publication Number Publication Date
AU2024307335A1 true AU2024307335A1 (en) 2026-04-16

Family

ID=93938355

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2024307335A Pending AU2024307335A1 (en) 2023-10-05 2024-10-04 Pharmaceutical composition containing uracil derivative

Country Status (4)

Country Link
JP (2) JP7674711B1 (https=)
AU (1) AU2024307335A1 (https=)
TW (1) TW202523309A (https=)
WO (1) WO2025005306A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12021552872A1 (en) * 2020-04-05 2022-03-21 Pfizer Compounds and methods for the treatment of covid-19
US11351149B2 (en) * 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
LT4122926T (lt) * 2021-04-14 2025-07-25 Shionogi & Co., Ltd. Triazino dariniai, turintys virusų replikaciją slopinantį poveikį, ir juos apimanti farmacinė kompozicija
JP7624093B2 (ja) * 2022-04-08 2025-01-29 塩野義製薬株式会社 ウイルス増殖阻害活性を有するウラシル誘導体およびそれらを含有する医薬組成物

Also Published As

Publication number Publication date
JP7674711B1 (ja) 2025-05-12
TW202523309A (zh) 2025-06-16
WO2025005306A1 (ja) 2025-01-02
JPWO2025005306A1 (https=) 2025-01-02
JP2025108531A (ja) 2025-07-23

Similar Documents

Publication Publication Date Title
JP7105430B1 (ja) ウイルス増殖阻害作用を有するトリアジン誘導体およびそれらを含有する医薬組成物
JP7466731B2 (ja) トリアジン誘導体を含有する経口投与する製剤
TW202320793A (zh) 含有三嗪衍生物之醫藥組合物
JP7236065B1 (ja) トリアジン誘導体を含有する医薬組成物
JP7273455B1 (ja) 新型コロナウイルス感染症治療用医薬
WO2023095860A1 (ja) ３ｃｌプロテアーゼ阻害剤及びｃｏｖｉｄ－１９治療用薬剤を組み合わせることを特徴とするｃｏｖｉｄ－１９治療用医薬
JP7261529B1 (ja) ウイルス増殖阻害作用を有するトリアジン誘導体の製造方法
CN116782904A (zh) 含有三嗪衍生物的医药组合物
AU2024307335A1 (en) Pharmaceutical composition containing uracil derivative
RU2806042C1 (ru) Триазиновые производные, имеющие ингибиторную активность в отношении репликации вируса, и содержащая их фармацевтическая композиция
JP7692546B1 (ja) ウラシル誘導体の製造方法
TWI916636B (zh) 新型冠狀病毒感染症治療用醫藥
US20260125365A1 (en) Triazine derivatives having virus replication inhibitory activity and pharmaceutical composition comprising the same
BR112022023272B1 (pt) Derivados de triazina tendo efeito inibidor de propagação de vírus e cocristal do mesmo com ácido fumárico
HK40114521A (en) Pharmaceutical composition containing triazine derivative